Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Assess Efficacy of 3'-Aminomethylnicotine-P.Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Smokers Who Want to Quit Smoking

NCT00318383 is registered in ClinicalTrials.gov with National Institute on Drug Abuse (NIDA) as lead sponsor.

NCT NCT00318383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00318383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Assess Efficacy of 3'-Aminomethylnicotine-P.Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Smokers Who Want to Quit Smoking
Lead sponsor
National Institute on Drug Abuse (NIDA)
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
December 31, 2007
Enrollment
313 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation